Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With ⅡA -ⅢA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study

NCT05825443 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT05825443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05825443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With ⅡA -ⅢA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2023
Completion date
April 1, 2029
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, immunotherapy